New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2014
05:57 EDTORMPOramed says Phase 2a ORMD-0801 study met all primary, secondary endpoints
Oramed Pharmaceuticals announced results from its Phase 2a clinical trial for its ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes. The trial was conducted under a United States FDA Investigational New Drug protocol. The Phase 2a study met all primary and secondary endpoints. 30 patients with type 2 diabetes took part in the trial in an in-patient setting for one week. Endpoints of safety as well as pharmacodynamic and pharmacokinetic effects were evaluated against a placebo control. For full information on the Phase 2a trial design and endpoints please see Clinical Trials. Full results are expected to be presented at a scientific conference in the future. "We are extremely pleased with the results which give a solid validation for Oramed's platform technology in general and our oral insulin program in particular," stated Oramed CEO Nadav Kidron. "Following on the results from this type 2 diabetes study we are gearing up to start a multi-center Phase 2b study later this year. We are also excited about the potential of this drug for type 1 diabetes and plan to initiate a Phase 2a FDA study for this indication in the near term."
News For ORMP From The Last 14 Days
Check below for free stories on ORMP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ORMP

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use